Imunon grants Douglas Vincent Faller 1,596 shares

The remarks characterize the stock grant as being in lieu of cash for a portion of the chief medical officer’s base salary.

Available on EDGAR 11/10/2026 - 07:15 PM EST Accepted by SEC EDGAR 11/10/2026 - 07:15 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Imunon, Inc. reported that Chief Medical Officer Douglas Vincent Faller received a grant of 1,596 shares of common stock on November 6, 2026, bringing his directly held position to 76,356 shares. The transaction was reported at $0.845 per share. The remarks describe the stock as granted in lieu of cash for a portion of base salary.

Insider Trade Summary

Grant/Award: 1,596 shares

Grant/Award 1 txn

Insider Faller Douglas Vincent

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	1,596	$0.845	$1K

Holdings After Transaction: Common Stock — 76,356 shares (Direct)

Key Figures

Shares granted: 1,596 shares Reported price per share: $0.845 per share Direct shares held after grant: 76,356 shares

3 metrics

Shares granted 1,596 shares Common stock grant on November 6, 2026

Reported price per share $0.845 per share Common stock grant on November 6, 2026

Direct shares held after grant 76,356 shares Following the November 6, 2026 grant

Key Terms

in lieu of cash, non-derivative

2 terms

in lieu of cash financial

"stock granted in lieu of cash for portion of base salary"

non-derivative technical

"Common Stock acquisition reported as non-derivative"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares did IMNN Chief Medical Officer Douglas Vincent Faller receive?

Douglas Vincent Faller received a grant of 1,596 shares of common stock on November 6, 2026. His directly held position afterward was 76,356 shares, and the transaction was reported at $0.845 per share.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Faller Douglas Vincent

(Last) (First) (Middle)

C/O IMUNON, INC.

997 LENOX DRIVE, SUITE 100

(Street)

LAWRENCEVILLE NEW JERSEY 08648

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Imunon, Inc. [ IMNN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2026		A		1,596	A	$0.845	76,356	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Stock Grant (26,741 shares) Stock granted in lieu of cash for portion of base salary (1.092 shares)

	/s/ Jeffrey W Church, Attorney in Fact for Douglas Faller	11/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)